Drugs / OXETHAZAINE
OXETHAZAINE
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT01336530 Comparator | Apr 2011 → Jan 2017 | radiation-induced disorder | MEDA Pharma GmbH & Co. KG | Terminated | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | OXETHAZAINE | ChEMBL registry synonym — accepted as the source's own label CHEMBL127592 ↗ |
| Known as | NSC-758444 | ChEMBL registry synonym — accepted as the source's own label CHEMBL127592 ↗ |
| Known as | Oxetacaina | ChEMBL registry synonym — accepted as the source's own label CHEMBL127592 ↗ |
| Known as | oxetacaine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01336530 ↗ |
| Known as | Strocain | ChEMBL registry synonym — accepted as the source's own label CHEMBL127592 ↗ |
| Known as | WY-806 | ChEMBL registry synonym — accepted as the source's own label CHEMBL127592 ↗ |
| Modality | Small molecule | — CHEMBL127592 ↗ |
| Route | Oral | “Suspension for oral intake 3-6 times per day for a maximum of 11 weeks.” NCT01336530 ↗ |